SPRB Spruce Biosciences, Inc.
Spruce Biosciences, Inc. (SPRB) is expected to report earnings on November 11, 2026, after the market close. The consensus earnings estimate is a loss of $5.66 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +12.1% since its last earnings release on August 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Spruce Biosciences, Inc.
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need.
Sector
Healthcare
Industry
Biotechnology